Phase I studies yield promising results for skin cancer drug

03/24/2010 | MarketWatch

A Phase I study showed PTI-188, Pain Therapeutics' metastatic melanoma drug candidate, led to almost 70% of patients having stable disease at the end of the study. A second Phase I trial showed the drug helped about 40% of patients achieve stable disease at the 14th week. The drug is a radiolabeled monoclonal antibody that attaches to and eliminates melanoma tumors.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA